The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA

Soft tissue sarcomas (STS) are a heterogeneous group of malignancies predominantly affecting children and young adults. Despite improvements in multimodal therapies, 5-year survival rates are only 50% and new treatment options in STS are urgently needed. To develop a rational combination therapy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Muenchow, Alina, Weller, Sandra, Hinterleitner, Clemens, Malenke, Elke, Bugl, Stefanie, Wirths, Stefan, Müller, Martin R., Schulze-Osthoff, Klaus, Aulitzky, Walter E., Kopp, Hans-Georg, Essmann, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445285/
https://www.ncbi.nlm.nih.gov/pubmed/32839432
http://dx.doi.org/10.1038/s41419-020-02910-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445285/
https://www.ncbi.nlm.nih.gov/pubmed/32839432
http://dx.doi.org/10.1038/s41419-020-02910-2

Ejemplares similares